SCHEMBL19332833

SCHEMBL19332833

C=CC(=O)N1CC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2cncnc21

nearest known ligand 0.67

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 19/20 0.67
▸ EGFR P00533 10/20 0.67
▸ LCK P06239 9/20 0.67
▸ ITK Q08881 6/20 0.67
▸ JAK3 P52333 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19332762 1.00 BTK (0.67) BTKEGFRLCKITKJAK3
SCHEMBL19332763 1.00 BTK (0.67) BTKEGFRLCKITKJAK3
SCHEMBL19332611 0.96 BTK (0.73) BTKEGFRLCKITKJAK3
SCHEMBL19332849 0.96 BTK (0.73) BTKEGFRLCKITKJAK3
SCHEMBL19332612 0.96 BTK (0.73) BTKEGFRLCKITKJAK3
SCHEMBL19332677 0.95 BTK (0.69) BTKEGFRLCKITKJAK3
SCHEMBL19332676 0.95 BTK (0.69) BTKEGFRLCKITKJAK3
SCHEMBL20893033 0.95 BTK (0.69) BTKEGFRLCKITKJAK3
SCHEMBL19332753 0.88 BTK (0.62) BTKEGFRLCKITKJAK3
SCHEMBL20892847 0.88 BTK (0.62) BTKEGFRLCKITKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115746000-A Compounds and methods for modulating bruton's tyrosine kinase 嘉兴和剂药业有限公司 2023-03-07 — — CN disclosed
CN-109071455-B Compounds and methods for modulating bruton's tyrosine kinase 嘉兴和剂药业有限公司 2022-08-02 — — CN disclosed
EP-3426637-B1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE ANGEL PHARMACEUTICAL CO LTD (CN) 2022-02-09 — — EP disclosed
EP-3426637-B1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE ANGEL PHARMACEUTICAL CO LTD (CN) 2022-02-09 — — EP disclosed
US-10870652-B2 Compounds and methods for modulating bruton's tyrosine kinase CORVUS PHARMACEUTICALS, INC. (US) 2020-12-22 — — US disclosed
US-10870652-B2 Compounds and methods for modulating bruton's tyrosine kinase CORVUS PHARMACEUTICALS, INC. (US) 2020-12-22 — — US disclosed
US-20190106423-A1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE CORVUS BIOPHARMACEUTICALS, LTD. (KY) 2019-04-11 — — US disclosed
US-20190106423-A1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE CORVUS BIOPHARMACEUTICALS, LTD. (KY) 2019-04-11 — — US disclosed
EP-3426637-A1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE Corvus Pharmaceuticals, Inc. (US) 2019-01-16 — — EP disclosed
WO-2017156495-A1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE CORVUS PHARMACEUTICALS, INC. (US) 2017-09-14 — — WO disclosed
WO-2017156495-A1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE CORVUS PHARMACEUTICALS, INC. (US) 2017-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106423-A1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE ABL1, BTK, LYN BTK 2/4885EGFR 711/4885LCK 6/4885
US-10870652-B2 Compounds and methods for modulating bruton's tyrosine kinase ABL1, BTK, LYN BTK 2/4885EGFR 711/4885LCK 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback